MBX Biosciences Q3 2026 Results: Net Loss of $62.4M, Loss Widens
MBX Biosciences reported a significant increase in operating expenses for the nine months ended September 30, 2026, with research and development costs rising to $81.5 million. The company's cash and marketable securities position strengthened to approximately $481.6 million following public offerings, while the accumulated deficit grew to $347.5 million. As of November 5, 2026, the company had 49,656,265 shares of common stock outstanding.
- Key figure
- Net loss $62.4M